The RMAT designation accelerates the development of regenerative medicine therapies for serious or life-threatening diseases
The goal of the agreement is to advance cell and gene therapy accessibility by enabling scalable and efficient cell therapy manufacturing
Galenicum will oversee development, manufacturing and supply, while Lupin will handle regulatory submissions, approvals, and commercialization and distribution of Semaglutide across 23 countries globally
The registrations grant Neurizon exclusive rights to use and defend its brand across its core operating regions
The new investment will fuel expansion of Avalon's Diagnostic Intelligence capabilities
The collaboration aims to accelerate the delivery of challenging DNA motifs with speed, precision, and reliability
The injectable borofalan (10B), developed by CNNC Headway—a subsidiary of China Isotope & Radiation Corporation (CIRC) under the China National Nuclear Corporation (CNNC)—has officially entered Phase I clinical trials
Waskyra is an ex vivo gene therapy that uses patients’ own CD34+ hematopoietic stem and progenitor cells, genetically engineered with a lentiviral vector
DNA nanorobots—tiny, self-assembling machines capable of detecting diseases in blood samples within 2–4 hours
Subscribe To Our Newsletter & Stay Updated